Abstract:Objective To analyze the suspicious results of serum HBV DNA by fluorescence quantitative PCR and develop appropriate countermeasures in order to improve the quality of detection of HBV DNA.Methods Blood samples of patients from the First Affiliated Hospital of Wenzhou Medical College from 2008 to 2011 were analyzed for HBV DNA by fluorescence quantitative PCR.1969 cases of suspicious results,judged by the rule of review the results of serum HBV DNA combined with the historical results,PCR amplification curve,HBV serum markers and clinical diagnosis,were analyzed and redetected by using of two different reagents,careHBV PCR Kit and careHBV PCR Kit V2,at the same time.The consistency and inconsistency ratio of the results were evaluated.Both the reasons of inconsistent and the undetected rates of careHBV PCR Kit were analyzed.The two reasons for the inconsistent results included the reagent related factors,e.g,showing no amplification curve caused by the false negative and abnormal low efficiency of amplification curve,and the non reagent related factors such as operating pollution and other sample factors.Results There were 115 154 blood samples were detected for HBV from 2008 to 2011 and 1969 samples (1.71％) with suspicious results were redetected.The consistency and inconsistency results were 1588 (80.65％) and 381 (19.35％),respectively.Every year from 2008 to 2011,the percentage of the inconsistent results caused by the reagent related factors were 18.87％,20.23％,51.33％ and 59.57％ respectively,which showed an increasing trend,and the percentage of inconsistent results caused by the nonreagent related factors were 81.13％,79.77％,48.67％ and 40.43％ respectively,which showed a declining trend year by year.The undetected rates of careHBV PCR Kit were 2.49％,4.08％,10.09％ and 14.47％ respectively,showing an increasing trend.Conclusions The redetection for the specimens with the suspicious results by using of different reagents can avoid the blind detection of HBV DNA and reduce the experimental error.All the clinical samples for quantitative HBV DNA including the mutations of HBV gene can be measured accurately and effectively,which is helpful to hepatitis B patients for antiviral therapy.

Monitoring of the Emergence of Hepatitis B Virus YMDD Variants by Fluorometric Real-Time PCR

Analysis of suspicious results of serum HBV DNA detected by fluorescence quantitative PCR

Detecting of the Hepatic Fibrotic Indexes and Serous Markers from Patients with Chronic Hepatitis B (chb)and Variation of HBV DNA YMDD

A Real-Time PCR Method Formonitoring YMDD Motif Mutations Associated with Lamivudine Resistance in Patients with HBVinfection

P.038 Differences of Ymdd Mutational Patterns, Pre-Core/core Promoter Mutations, Serum Viral Loads in Lamivudine-Resistant Hepatitis B Genotypes B and C

Detection of HBV lamivudine-resistant mutants with the method of PCR-RFLP in combination with PCR clone sequencing

Analysis of YMDD Mutants in Hepatitis B Virus Infected Patients with Lamivudine Therapy by Restriction Fragment Length Polymorphism (RFLP) of the PCR Products

Comparison of PCR-fluorescent-probe assay with DNA sequencing analysis for the detection of Hepatitis B virus YMDD mutation

Rapid and High Throughput Detection of Hbvymdd Mutants with Fluorescence Polarization

YMDD Variants of HBV DNA Polymerase Gene: Rapid Detection and Clinicopathological Analysis with Long-Term Lamivudine Therapy after Liver Transplantation.

Detection and Analysis of Gene Mutation of HBV DNA

Detection of YMDD mutation in HBV polymerase gene region with nested PCR

Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection.

Dynamics of hepatitis B virus variations during lamivudine treatment

Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C

Application of PCR‐LDR‐nucleic Acid Detection Strip in Detection of YMDD Mutation in Hepatitis B Patients Treated with Lamivudine

Reverse Line Probe Hybridization Assay for Detection of Lamivudine-Resistant Chronic Hepatitis B Virus

Detection and Identification of Emergence of HBV YMDD Motif Mutation During Lamivudine Treatment by Hybridization to an Oligonucleotide Array

Multiplex Locked Nucleic Acid Probes for Analysis of Hepatitis B Virus Mutants Using Real-Time PCR

Detection and RFLP Analysis of the Polymerase Gene Mutation of HBV DNA

Simultaneous Detection of Two Major Lamivudine-Resistant Mutants Using Competitively Differentiated-Pcr.